Publications by authors named "Esther N M Overkleeft"
Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
Bodine P S Belderbos Sander Bins Roelof W F van Leeuwen Esther Oomen-de Hoop Nelly van der Meer Esther N M Overkleeft
Clin Cancer Res
February 2018
Article Synopsis
- Current clinical research is investigating the combination of taxane treatments, such as cabazitaxel, with AR-targeted agents like enzalutamide for metastatic castration-resistant prostate cancer (mCRPC).
- A study found that adding enzalutamide to cabazitaxel treatment resulted in a significant 22% reduction in cabazitaxel exposure, highlighting a potential drug-drug interaction due to enzalutamide's effect on metabolizing enzymes.
- While this combination did not lead to increased toxicity and showed promising PSA response, careful consideration of drug interactions is crucial, especially with studies suggesting a lower dose of cabazitaxel could be clinically relevant.
Objective: To evaluate whether nuclear activity as measured by the disodium phosphate 32P (32P) uptake test for uveal melanoma is of prognostic value and corresponds to known prognostic factors.
Methods: A retrospective analysis of 121 patients with choroidal and/or ciliary body melanoma, tested with the 32P uptake test before enucleation between January 1, 1973, and December 31, 1976, at the Leiden University Medical Center. We obtained the 25-year follow-up information of this group of patients and compared the 32P test results and histopathological variables with the long-term survival rates.